NCT03250039View on ClinicalTrials.gov

Absorption, Metabolism, Excretion and Absolute Bioavailability

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 10, 2017

Primary Completion Date

September 15, 2017

Study Completion Date

September 15, 2017

Conditions
Healthy
Interventions
DRUG

PF-04965842

14C labeled PF-04965842

DRUG

Absolute Bioavailability

Oral dose of unlabeled PF-04965842 and an IV dose of 14C labeled PF- 04965842

Trial Locations (2)

9713 GZ

PRA Health Sciences, Groningen

9728 NZ

PRA Health Sciences, Groningen

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT03250039 - Absorption, Metabolism, Excretion and Absolute Bioavailability | Biotech Hunter | Biotech Hunter